Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose excretion and reduce cardiovascular (CV) deaths and hospitalizations for heart failure (HHF) among patients with type 2 diabetes. The relative CV efficacy and safety of dapagliflozin according to base...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JAMA Cardiol
Main Authors: Zelniker, Thomas A., Raz, Itamar, Mosenzon, Ofri, Dwyer, Jamie P., Heerspink, Hiddo H. J. L., Cahn, Avivit, Goodrich, Erica L., Im, Kyungah, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P. H., Gause-Nilsson, Ingrid, Langkilde, Anna Maria, Sabatine, Marc S., Wiviott, Stephen D.
Format: Artigo
Sprog:Inglês
Udgivet: American Medical Association 2021
Fag:
Original Investigation
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8047725/
https://ncbi.nlm.nih.gov/pubmed/33851953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2021.0660
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker